Insider Selling: Alpha Tau Medical (NASDAQ:DRTS) CFO Sells $248,220.00 in Stock

Alpha Tau Medical Ltd. (NASDAQ:DRTS) CFO Raphi Levy sold 17,730 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $14.00, for a total transaction of $248,220.00. Following the completion of the sale, the chief financial officer directly owned 90,180 shares in the company, valued at $1,262,520. This trade represents a 16.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Raphi Levy also recently made the following trade(s):

• On Monday, July 6th, Raphi Levy sold 2,270 shares of Alpha Tau Medical stock. The stock was sold at an average price of $14.00, for a total transaction of $31,780.00.
• On Thursday, July 2nd, Raphi Levy sold 17,873 shares of Alpha Tau Medical stock. The shares were sold at an average price of $13.00, for a total transaction of $232,349.00.
• On Wednesday, July 1st, Raphi Levy sold 2,127 shares of Alpha Tau Medical stock. The shares were sold at an average price of $13.02, for a total transaction of $27,693.54.
• On Tuesday, June 30th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The shares were sold at an average price of $12.00, for a total value of $240,000.00.
• On Thursday, June 25th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The stock was sold at an average price of $11.00, for a total value of $220,000.00.
• On Tuesday, June 23rd, Raphi Levy sold 17,500 shares of Alpha Tau Medical stock. The stock was sold at an average price of $9.55, for a total value of $167,125.00.
• On Wednesday, June 3rd, Raphi Levy sold 32,500 shares of Alpha Tau Medical stock. The shares were sold at an average price of $10.83, for a total value of $351,975.00.

Alpha Tau Medical Trading Down 4.4%

Shares of DRTS stock traded down $0.63 on Wednesday, hitting $13.64. The stock had a trading volume of 278,117 shares, compared to its average volume of 591,397. The company’s 50 day moving average price is $11.68 and its 200-day moving average price is $9.23. Alpha Tau Medical Ltd. has a 1 year low of $3.00 and a 1 year high of $14.40. The company has a debt-to-equity ratio of 0.09, a current ratio of 7.79 and a quick ratio of 7.79. The firm has a market capitalization of $1.23 billion, a P/E ratio of -13.12 and a beta of 1.17.

Alpha Tau Medical (NASDAQ:DRTS) last released its earnings results on Monday, August 10th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.36). The business had revenue of $0.10 million during the quarter, compared to the consensus estimate of $0.14 million. Analysts anticipate that Alpha Tau Medical Ltd. will post -0.67 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Zacks Research upgraded shares of Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a report on Monday, August 3rd. Benchmark reiterated a “buy” rating on shares of Alpha Tau Medical in a report on Thursday, July 23rd. Piper Sandler raised their price target on shares of Alpha Tau Medical from $5.00 to $8.00 and gave the company a “neutral” rating in a research report on Tuesday, May 19th. HC Wainwright upped their price objective on Alpha Tau Medical from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Alpha Tau Medical in a research note on Friday, July 17th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $12.80.

Hedge Funds Weigh In On Alpha Tau Medical

Institutional investors and hedge funds have recently made changes to their positions in the stock. Everhart Financial Group Inc. acquired a new stake in Alpha Tau Medical in the second quarter valued at approximately $126,000. Renaissance Technologies LLC acquired a new position in Alpha Tau Medical during the 1st quarter worth approximately $286,000. Principal Financial Group Inc. purchased a new stake in shares of Alpha Tau Medical in the 1st quarter valued at approximately $132,000. Millennium Management LLC raised its holdings in shares of Alpha Tau Medical by 185.7% in the 4th quarter. Millennium Management LLC now owns 107,815 shares of the company’s stock valued at $534,000 after purchasing an additional 70,081 shares in the last quarter. Finally, Mariner LLC lifted its position in shares of Alpha Tau Medical by 1.6% during the 4th quarter. Mariner LLC now owns 125,165 shares of the company’s stock worth $620,000 after purchasing an additional 1,915 shares during the last quarter. 2.65% of the stock is owned by institutional investors and hedge funds.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.